Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (10) | Back to Search
Economic evaluation of carfilzomib (car), ixazomib (ixa), elotuzumab (elo), or daratumumab (dar) with lenalidomide & dexamethasone (len+dex) vs len+dex in relapsed/refractory multiple myeloma (r/r mm)
- In: Poster presentation
- At: Seoul (South Korea) (2017)
- Type: Poster
- Poster code: POS-SAPS-002
- By: ABRAHAM, Ivo (University Of Arizona, Pharmacy Practice and Science, Tucson, United States)
- Co-author(s): Nimer Alsaid: Center for Health Outcomes and PharmacoEconomic Research, University Of Arizona College of Pharmacy, Tucson, United States
Ali McBride: Banner University Medical Center , Tucson, United States;, University of Arizona Cancer Center, Tucson, United States
Abdulaali Mutairi: Center for Health Outcomes and PharmacoEconomic Research, University Of Arizona College of Pharmacy, Tucson, United States
Amit Agarwal: Banner University Medical Center, Tucson, United States;, University of Arizona Cancer Center, Tucson, United States
Faiz Anwer: Banner University Medical Center, Tucson, United States;, University of Arizona Cancer Center, Tucson, United States
Ivo Abraham: Center for Health Outcomes and PharmacoEconomic Research, University Of Arizona College of Pharmacy, Tucson, United States - Abstract:
Background
CAR, IXA, ELO, and DAR in triplet combination with LEN+DEX have shown superior efficacy over LEN+DEX in R/R MM, but their comparative efficacy and cost effectiveness have not been estimated.Purpose
To perform cost-effectiveness and cost-utility evaluations for the four triplet regimens used in R/R MM.Methods
Network meta-analysis [NMA] and .. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023